You are here

Home » Content

AKTİVATOR PROTEİN-1’İN ETKİSİNİ KULLANARAK ONKOJENİK TRANSFORMASYONU YÖNLENDİRMEK

MANAGEMENT OFONCOGENIC TRANSFORMATION BY INTERFERING WITH THE ACTION OFACTIVATOR PROTEIN-1

Journal Name:

  • İstanbul Tıp Fakültesi Dergisi

Publication Year:

  • 2008

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Immediate Early Genes (IEGs) are the foremost genes to respond to any stimuli within the cell. This group of genes are in fact transcription factors which are associated with the growth, proliferation, differentiation and apoptosis of the cells. Fos proteins produced by c-fos gene, which is an IEG, and Jun proteins produced by c-jun gene, which is also an IEG, are the components of the transcription factor complex, namely the Activator Protein-1 (AP- 1), and they act together. The members of the AP-1 complex modulate various gene expressions. All AP-1 proteins regulate certain aspects of the cellular responses to growth factors. These components are critically linked to many cellular processes including growth, proliferation, differentiation, apoptosis, and oncogenic transformation.Carcinogenesis resulting from the impairment in the cellular processes controlled by IEGs and AP-1 has been described. Besides the vital importance of their normal cellular expressions, the abnormal expressions of IEGs and AP-1 could cause serious problems such as oncogenic transformation. There are several ongoing studies about the substances and effectors causing overexpression or inhibition of AP-1. If the stages of oncogenic transformation and the role of AP-1 and IEGs in this transformation can be illuminated, carcinogenesis could be taken under control as well as some of the peculiarities of malignant cells could be beneficial for the treatments of various diseases.
Bookmark/Search this post with
Abstract (Original Language): 
Bir uyar›yla karfl›laflan hücrelerde, uyarana ilk yan›t veren genler IEG (Immediate Early Gene) grubundaki genlerdir. Bu genler hücre büyümesi, ço¤almas›, farkl›laflmas› ve hücrenin programlanm›fl ölümü (apoptozis) ile ilgili transkripsiyon faktörleridir. Bir IEG olan c-fos geninin üretti¤i Fos proteinleri, yine bir IEG olan c-jun geninin üretti¤ i Jun proteinleri transkripsiyon faktör kompleksi Aktivator Protein-1 (AP-1)’in komponentleri olarak birlikte ifllev görürler. AP-1 kompleksinin üyeleri farkl› gen ekspresyonlar›n› ve büyüme faktörlerine hücresel yan›t›n baz› yönlerini düzenlerler. Bu komponentler büyüme, ço¤alma, farkl›laflma, programlanm›fl hücre ölümü ve onkojenik transformasyon gibi hücresel süreçlerde kilit rolü oynarlar. Karsinogenezin, IEG ve AP-1 taraf›ndan kontrol edilen hücresel süreçlerdeki bozuklu¤un bir sonucu oldu¤u tan›mlanm›flt›r. IEG ve AP-1’in hücrelerdeki normal ekspresyonlar› n›n yaflamsal önemi vard›r ancak anormal ekspresyonlar›, onkojenik transformasyon gibi ciddi sorunlar do- ¤urur. AP-1’in ekspresyonunu art›ran veya azaltan maddeler ve etkenler konusundaki çal›flmalar devam etmektedir. Onkojenik transformasyonun aflamalar› ve bu transformasyonda IEG ve AP-1’in rolü tam olarak ayd›nlat›labilirse karsinogenez kontrol edilebilir bir duruma gelebilecek hatta kanser hücrelerinin baz› özelliklerinden çeflitli hastal› klar›n tedavisinde yararlan›labilecektir.
FULL TEXT (PDF): 
PDF icon arastirmax-aktivator-protein-1in-etkisini-kullanarak-onkojenik-transformasyonu-yonlendirmek.pdf
  • 3
94-98
  • English

REFERENCES

References: 

1- Angel P, Imagawa M, Chiu R, Stein B, Imbra RJ, Rahmsdorf
HJ, Jonat C, Herrlich P, Karin M. Phorbol ester-inducible genes
contain a common cis element recognized by a TPA-modulated
trans-acting factor. Cell 1987;49:729-739.
2- Angel P, Karin M . The role of Jun, Fos and the AP-1 complex
in cell-proliferation and transformation. Biochem Biophys
Acta 1991;1072:129-157.
3- Anisimov VN. Biology of aging and cancer. Cancer Control
2007;14:23-31.
4- Bakiri L, Matsuo K, Wisniewvska M, Wagner EF, Yaniv M.
Promoter specificity and biological activity of tethered AP-1
dimers. Mol Cell Biol 2002;22:4952-4964.
5- Bossis G, Malnou CE, Farras R, Andermarcher E, Hipskind
R, Rodriguez M, Schmidt D, Muller S, Jariel-Encontre I, Piechaczyk
M. Down-regulation of c-Fos/c-Jun AP-1 dimer
activity by sumoylation. Mol Cell Biol 2005;25:6964-6979.
6- Chun KS, Kim SH, Song YS, Surh YJ. Celecoxib inhibits
phorbol ester-induced expression of COX-2 and activation
of AP-1 and p38 MAP kinase in mouse skin. Carcinogenesis
2004;25:713-722.
7- Clayton DF. The genomic action potential. Neurobiol Learn
Mem. 2000;74:185-216.
8- Crighton D, Ryan KM. Splicing DNA-damage responses to
tumour cell death. Biochim Biophys Acta 2004;1705:3-
1715.
9- Ding M, Huang C, Lu Y, Bowman L, Castranova V, Vallyathan
V. Involvement of protein kinase C in crystalline silicainduced
activation of the MAP kinase and AP-1 pathway.
Am J Physiol Lung Cell Mol Physiol 2006;290:291-297.
10- Dong Z., Birer MJ, Watts RG, Matrisian LM, Colburn NH.
Blocking of tumor promoter-induced AP-1 activity inhibits
induced transformation in JB6 mouse epidermal cells. Proc
Natl Acad Sci USA 1994;91:609–613.
11- Eferl R, Wagner EF. AP-1: A double-edged sword in tumorigenesis.
Nat Rev Cancer 2003;3:859-868.
12- Fleischmann A, Hafezi F, Elliott C, Reme EC, Rüther U,
Wagner FE. Fra-1 replaces c-Fos-dependent functions in mice.
Genes & Dev 2000;14:2695-2700.
13- Foletta VC. Transcription factor AP-1, and the role of Fra-2.
Immunol Cell Biol 1996;74: 121-133.
14- Franchi A, Calzolari A, Zampi G. Immunohistochemical detection
of c-fos and c-jun expression in osseous and cartilaginous
tumours of the skeleton. Virchows Arch.
1998;432:515-519.
15- Funk JO. Cancer cell cycle control. Anticancer Res
1999;19:4772-4780.
16-Glover JNM, Harrison SC. Crystal structure of the Heterodimeric
bZIP Transcription Factor c-Fos/ c-Jun Bound to
DNA. Nature 1995;373:257-261.
17- Greenhalgh DA, Wang XJ, Eckhardt JN, Roop DR. 12-Otetradecanoylphorbol-
13-acetate promotion of transgenic
mice expressing epidermal-targeted v-fos induces rasHA-activated
papillomas and carcinomas without p53 mutation: association
of v-fos expression with promotion and tumor autonomy.
Cell Growth Differ 1995;6:579-586.
18- Hennigan RF, Stambrook PJ. Dominant negative c-jun inhibits
activation of the cyclin D1 and cyclin E kinase complexes.
Mol Biol Cell 2001;12:2352-2363.
19- Hou DX, Kai K, Li JJ, Lin S, Terahara N, Wakamatsu M, Fujii
M, Young MR, Colburn N. Anthocyanidins inhibit activator
protein 1 activity and cell transformation: structure-activity
relationship and molecular mechanisms. Carcinogenesis
2004;25:29-36.
20- Huang Q, Shen HM, Ong CN. Inhibitory effect of emodin on
tumor invasion through suppression of activator protein-1
and nuclear factor-kappaB. Biochem Pharmacol
2004;68:361-371.
21- Jansen AP, Camalier CE, Colburn NH. Epidermal expression
of the translation inhibitor programmed cell death 4 suppresses
tumorigenesis. Cancer Res 2005;65:6034-6041.
22- Jin C, Li H, Murata T, Sun K, Horikoshi M, Chiu R, Yokoyama
KK. JDP2, a repressor of AP-1, recruits a histone deacetylase
3 complex to inhibit the retinoic acid-induced differentiation
of F9 cells. Mol Cell Biol 2002;22:4815-4826.
23- Jochum W, Passegue E, Wagner EF. AP-1 in mouse development
and tumorigenesis. Oncogene 2001;20:2401_2412.
24- Kang JS, Yoon YD, Lee KH, Park SK, Kim HM. Costunolide
inhibits interleukin-1beta expression by down-regulation
of AP-1 and MAPK activity in LPS-stimulated RAW 264.7
cells. Biochem Biophys Res Commun 2004;313:171-177.
25- Karin M, Zhend-gang L, Zandi E. AP-1 function and regulation.
Curr Opin Cell Biol 1997;9:240-246.
26-Keklikoglu N. The localization of Fos B, a member of
transcription factor AP-1 family, in rat odontoblasts and pulpal
undifferentiated ectomesenchymal cells. Folia Histochem
Cytobiol 2004;42:191-193.
27- Lee CS, Charalambous D. Immunohistochemical localisation
of the c-fos oncoprotein in pancreatic cancer. Zentralbl
Pathol 1994;140:271-275.
28- Lee SO, Jeong YJ, Im HG, Kim CH, Chang YC, Lee IS. Silibinin
suppresses PMA-induced MMP-9 expression by
blocking the AP-1 activation via MAPK signaling pathways
in MCF-7 human breast carcinoma cells. Biochem Biophys
Res Commun 2007;354:165-171.
29- Lin S, Li JJ, Fujii M, Hou DX. Rhein inhibits TPA-induced
activator protein-1 activation and cell transformation by
blocking the JNK-dependent pathway. Int J Oncol
2003;22:829-833.
30- Liu Y, Lu C, Shen Q, Munoz-Medellin D, Kim H, Brown
PH. AP-1 blockade in breast cancer cells causes cell cycle
arrest by suppressing G1cyclin expression and reducing
cyclin-dependent kinase activity. Oncogene 2004;23:8238-
8246.
Onkojenik transformasyonu yönlendirmek
‹stanbul T›p Fakültesi Dergisi Cilt / Volume: 71 • Say› / Number: 3 • Y›l/Year: 2008
- 97 -
31- Liu Y, Ludes-Meyers J, Zhang Y, Munoz-Medellin D, Kim
HT, Lu C, Ge G, Schiff R, Hilsenbeck SG, Osborne CK,
Brown PH. Inhibition of AP-1 transcription factor causes
blockade of multiple signal transduction pathways and inhibits
breast cancer growth. Oncogene 2002;21:7680-7689.
32- Lorenzini A, Tresini M, Mawal-Dewan M, Frisoni L, Zhang
H, Allen RG, Sell C, Cristofalo VJ. Role of the
Raf/MEK/ERK and the PI3K/Akt(PKB) pathways in fibroblast
senescence. Exp Gerontol 2002;37:1149-1156.
33- Lu C, Shen Q, Dupre E, Kim H, Hilsenbeck S, Brown PH.
cFos is critical for MCF-7 breast cancer cell growth. Oncogene
2005;24:6516-6524.
34- Ludes-Meyers JH, Liu Y, Munoz-Medellin D, Hilsenbeck
SG, Brown PH. AP-1 blockade inhibits the growth of normal
and malignant breast cells. Oncogene 2001;20:2771-2780.
35- Milde-Langosch K. The Fos family of transcription factors
and their role in tumourigenesis. Eur J Cancer
2005;41:2449-2461.
36- Pitot HC. Multistage carcinogenesis--genetic and epigenetic
mechanisms in relation to cancer prevention. Cancer Detect
Prev 1993;17:567-573.
37- Qi X, Borowicz S, Pramanik R, Schultz RM, Han J, Chen G.
Estrogen receptor inhibits c-Jun-dependent stress-induced
cell death by binding and modifying c-Jun activity in human
breast cancer cells. J Biol Chem 2004;279:6769-6777.
38- Rajapakse N, Kim MM, Mendis E, Huang R, Kim SK. Carboxylated
chitooligosaccharides (CCOS) inhibit MMP-9
expression in human fibrosarcoma cells via down-regulation
of AP-1. Biochim Biophys Acta 2006;1760:1780-1788.
39- Ramirez CJ, Haberbusch JM, Soprano DR, Soprano KJ. Retinoic
acid induced repression of AP-1 activity is mediated
by protein phosphatase 2A in ovarian carcinoma cells. J Cell
Biochem 2005;96:170-182.
40- Redell MS, Tweardy DJ. Targeting transcription factors for
cancer therapy. Curr Pharm Des 2005;11:2873-2887.
41- Roche E, Buteau J, Aniento I, Reig JA, Soria B, Prentki M.
Palmitate and oleate induce the immediate-early response
genes c-fos and nur-77 in the pancreatic beta-cell line INS-
1. Diabetes 1999;48:2007-2014.
42- Shah SA, Volkov Y, Arfin Q, Abdel-Latif MM, Kelleher D.
Ursodeoxycholic acid inhibits interleukin 1 beta [corrected]
and deoxycholic acid-induced activation of NF-kappaB and
AP-1 in human colon cancer cells. Int J Cancer
2006;118:532-539.
43- Sheerin A, Thompson KS, Goyns MH. Altered composition
and DNA binding activity of the AP-1 transcription factor
during the ageing of human fibroblasts. Mec Ageing Dev
2001;122:1813-1824.
44- Shirsat NV, Shaikh SA. Overexpression of the immediate
early gene fra-1 inhibits proliferation, induces apoptosis, and
reduces tumourigenicity of c6 glioma cells. Exp Cell Res
2003;291:91-100.
45- Stewart SA. Telomere maintenance and tumorigenesis: an
"ALT"ernative road. Curr Mol Med 2005;5:253-257.
46- de Sousa SO, Mesquita RA, Pinto DS Jr, Gutkind S. Immunolocalization
of c-Fos and c-Jun in human oral mucosa and
in oral squamous cell carcinoma. J Oral Pathol Med
2002;31:78-81.
47- Tresini M, Lorenzini A, Frisoni L, Allen RG, Cristofalo VJ.
Lack of Elk-1 phosphorylation and dysregulation of the extracellular
regulated kinase signaling pathway in senescent
human fibroblast. Exp Cell Res 2001;269:287-300.
48- Wang Y, Li Y, Qi X, Yuan W, Ai J, Zhu C, Cao L, Yang H,
Liu F, Wu X, Liu M. TRIM45, a novel human RBCC/TRIM
protein, inhibits transcriptional activities of ElK-1 and AP-1.
Biochem Biophys Res Commun 2004:8;323:9-16.
49- Wu Q, Chen Z, Su W. Mechanism of inhibition on activator
protein-1 activity by all-trans retinoic acid in gastric cancer
cells. Chin Med J (Engl) 2000;113:972-976.
50- Young MR, Li JJ, Rincon M, Flavell RA, Sathyanarayana
BK, Hunziker R, Colburn N. Transgenic mice demonstrate
AP-1 (activator protein-1) transactivation is required for tumor
promotion. Proc Natl Acad Sci U S A. 1999 ;96:9827-
9832.
51- Yuksel M, Okajima K, Uchiba M, Okabe H. Gabexate mesilate,
a synthetic protease inhibitor, inhibits lipopolysaccharide-
induced tumor necrosis factor-alpha production by inhibiting
activation of both nuclear factor-kappaB and activator
protein-1 in humanmonocytes. J Pharmacol Exp Ther
2003;305:298-305.
52- Zhang Z, Li M, Rayburn ER, Hill DL, Zhang R, Wang H.
Oncogenes as Novel Targets for Cancer Therapy (Part III):
Transcription Factors. Am J Pharmacogenomics 2005;5:327-
338.

Thank you for copying data from http://www.arastirmax.com